Targeting Energy Expenditure—Drugs for Obesity Treatment
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Obesity and overweight are associated with lethal diseases. In this context, obese and overweight individuals infected by COVID-19 are at greater risk of dying. Obesity is treated by three main pharmaceutical approaches, namely suppressing appetite, reducing energy intake by impairing absorption, and increasing energy expenditure. Most compounds used for the latter were first envisaged for other medical uses. However, several candidates are now being developed explicitly for targeting obesity by increasing energy expenditure. This review analyzes the compounds that show anti-obesity activity exerted through the energy expenditure pathway. They are classified on the basis of their development status: FDA-approved, Withdrawn, Clinical Trials, and Under Development. The chemical nature, target, mechanisms of action, and description of the current stage of development are described for each one.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 2×
“Whereas healthy eating and exercise is undoubted the best way to prevent obesity, this can be not enough for individuals with already developed obesity [2].”
BackgroundThe mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
Long-term weight loss maintenance
Wing, R. R., & Phelan, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.1.222s · Cited by 1,941 · cited 2×
“diet and exercise are the safest and healthiest approaches, it has been reported that they are only long-term effective in a small percentage of individuals [4].”
BackgroundTGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · cited 1×
“Consequently, INT-777 activity triggers thermogenesis in BAT and the muscle, thereby causing energy expenditure [92].”
BackgroundCellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
A Creatine-Driven Substrate Cycle Enhances Energy Expenditure and Thermogenesis in Beige Fat
Kazak, L., Chouchani, E. T., Jedrychowski, M. P., Erickson, B. K., Shinoda, K., Cohen, P., Vetrivelan, R., Lu, G. Z., Laznik-Bogoslavski, D., Hasenfuss, S. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.035 · Cited by 787 · cited 1×
“More recently, the creatine cycle as a new mechanism related to thermogenesis in beige adipocytes was reported [7].”
BackgroundTreatment of Obesity with Celastrol
Liu, J., Lee, J., Salazar Hernandez, M. A., Mazitschek, R., & Ozcan, U. (2015) · Cell · doi:10.1016/j.cell.2015.05.011 · Cited by 726
Cellular bioenergetics as a target for obesity therapy
Tseng, Y.-H., Cypess, A. M., & Kahn, C. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3138 · Cited by 591 · cited 5×
“In this process, the hydrolysis of triglycerides liberate fatty acids (FAs) and heat, and then fatty acids converted to FA-acyl-CoA are esterified back to triglycerides to close the futile cycle [5].”
BackgroundInfluentialClément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W. K., Connors, H., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30364-8 · Cited by 492 · cited 1×
“Setmelanotide is used as replacement therapy for POMC deficiency to treat obesity in genetically severe obesity disorders involving impaired POMC neuronal function [27,28].”
Background2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of Death
Grundlingh, J., Dargan, P. I., El-Zanfaly, M., & Wood, D. M. (2011) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0162-6 · Cited by 470
Metformin: Mechanisms in Human Obesity and Weight Loss
Yerevanian, A., & Soukas, A. A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00335-3 · Cited by 414 · cited 1×
“However, the mechanism by which this drug suppresses appetite is still being elucidated [33].”
BackgroundBray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
Larsen, T. M., Toubro, S., van Baak, M. A., Gottesdiener, K. M., Larson, P., Saris, W. H., & Astrup, A. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.4.780 · Cited by 179 · cited 1×
“However, in a study involving obese non-diabetic young men, it was not found to trigger a chronic thermogenic effect [99].”
BackgroundChen, K. Y., Muniyappa, R., Abel, B. S., Mullins, K. P., Staker, P., Brychta, R. J., Zhao, X., Ring, M., Psota, T. L., Cone, R. D., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4024 · Cited by 174 · cited 1×
“Located in the hypothalamus, the MC4 receptor is a crucial regulator of energy homeostasis that modulates food intake, increases energy expenditure, and causes weight loss when chronically activated [26].”
BackgroundHewagalamulage, S. D., Lee, T. K., Clarke, I. J., & Henry, B. A. (2016) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2016.03.004 · Cited by 167
Goldgof, M., Xiao, C., Chanturiya, T., Jou, W., Gavrilova, O., & Reitman, M. L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568204 · Cited by 138 · cited 1×
“More recently, in dose-ranging experiments in mice, the authors found a balanced dose (about 89 mg/kg/day) where the compound did not produce side effects like reduced water and food intake but did cause a loss of fat mass, reduced hepatic steatosis, and improved glucose tolerance [62].”
BackgroundResveratrol and obesity: can resveratrol relieve metabolic disturbances?
de Ligt, M., Timmers, S., & Schrauwen, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.012 · Cited by 135
Tokubuchi, I., Tajiri, Y., Iwata, S., Hara, K., Wada, N., Hashinaga, T., Nakayama, H., Mifune, H., & Yamada, K. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171293 · Cited by 121 · cited 1×
“reported that metformin reduces the volume of visceral fat, thereby improving energy metabolism, and they suggested that this effect could be due to forcing metabolism to switch to fat oxidation and the upregulation of adaptive thermogenesis, in addition to its anorexic effect [35].”
BackgroundThe efficiency of cellular energy transduction and its implications for obesity
Harper, M.-E., Green, K., & Brand, M. D. (2008) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155357 · Cited by 121
Villicev, C. M., Freitas, F. R. S., Aoki, M. S., Taffarel, C., Scanlan, T. S., Moriscot, A. S., Ribeiro, M. O., Bianco, A. C., & Gouveia, C. H. A. (2007) · Journal of Endocrinology · doi:10.1677/joe.1.07066 · Cited by 120 · cited 4×
“Modulation of this receptor is associated with decrease in body weight and anti-diabetogenic properties [71,74].”
BackgroundInfluentialAcute effect of L‐796568, a novel β3‐adrenergic receptor agonist, on energy expenditure in obese men
van Baak, M. A., Hul, G. B. J., Toubro, S., Astrup, A., Gottesdiener, K. M., DeSmet, M., & Saris, W. H. M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.122527 · Cited by 103 · cited 2×
“6 nmol/L) and a high specificity, thus causing fat mass changes [98].”
BackgroundBryzgalova, G., Effendic, S., Khan, A., Rehnmark, S., Barbounis, P., Boulet, J., Dong, G., Singh, R., Shapses, S., Malm, J., et al. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.06.010 · Cited by 94
Hypothalamic obesity: prologue and promise
Abuzzahab, M. J., Roth, C. L., & Shoemaker, A. H. (2019) · Hormone Research in Paediatrics · doi:10.1159/000496564 · Cited by 71 · cited 1×
“Furthermore, caffeine and ephedrine have been used in combination to induce weight loss through increased energy expenditure and reduced appetite by binding to the βadrenergic receptor (ephedrine) and adenosine receptor (caffeine) [38].”
BackgroundCombination phentermine and topiramate extended release in the management of obesity.
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041505 · Cited by 38
Fu, Y.-Y., Zhang, M., Turner, N., Zhang, L.-N., Dong, T.-C., Gu, M., Leslie, S. J., Li, J.-Y., Nan, F.-J., & Li, J. (2013) · Diabetologia · doi:10.1007/s00125-013-2987-9 · Cited by 35
Cited by
Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149
“analogs of PYY or amylin) reduce energy intake, long-term weight loss and maintenance in people with obesity may require strategies that also promote preservation of or increased energy expenditure [18,19].”
BackgroundHope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Metadata
- Authors
- Jimenez-Munoz, C. M., López, M., Albericio, F., & Makowski, K.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2021-05-06
- Volume
- 14
- Issue
- 5
- Pages
- 435
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W3159450286
- Cited by
- 35
- References
- 26
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.